Z
Zai Lab Limited (ZLAB)
NGM – Real vaqt narxi. Valyuta: USD
18.00
+0.49 (2.80%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
18.08
+0.08 (0.44%)
Bozordan keyin: Mar 27, 2026, 5:58 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
18.00
+0.49 (2.80%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
18.08
+0.08 (0.44%)
Bozordan keyin: Mar 27, 2026, 5:58 PM EDT
Zai Lab Limited, biopharmaceutical kompaniyasi, onkologiya, immunologiya, nevrologiya va yuqumli kasalliklar sohalarida tibbiy sharoitlarni davolashga qaratilgan mahsulotlarni kashf qilish, ishlab chiqish va tijoratlashtirishga e'tibor qaratadi. Uning tijoriy mahsulotlari qatoriga tuxumdon saratonini davolash uchun og'iz orqali yuboriladigan poli (ADP-riboza) polimeraza 1/2 ingibitori Zejula; umumiy miyasteniya gravis va surunkali yallig'lanishli demiyelinatsiyalovchi polinevropatiya uchun inson IgG1 antitel fragmenti VYVGART; hamjamiyatda orttirilgan bakterial pnevmoniya va teri va teri tuzilmalarining o'tkir bakterial infektsiyalari uchun NUZYRA; glial blastoma multiforme uchun Optune; oshqozon-ichak stromal o'smalari uchun Qinlock; Acinetobacter baumannii-calcoaceticus kompleksidan kelib chiqqan shifoxonada orttirilgan va ventilyator bilan bog'liq bakterial pnevmoniyani davolash uchun Xacduro; va ROS proto-onkogen 1 va mayda hujayrali o'pka saratonini davolash uchun Augtyro kiradi. Zai Lab Limited niraparibni ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun Tesaro, Inc. bilan litsenziya va hamkorlik shartnomalariga ega; Tumor Treating Fieldsni ishlab chiqish va tijoratlashtirish uchun NovoCure Ltd.; ripretinibni ishlab chiqish va tijoratlashtirish uchun Deciphera Pharmaceuticals, LLC; omadatsiklini ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun Paratek Bermuda Ltd.; efgartigimodni ishlab chiqish va tijoratlashtirish uchun argenx BV; repotrectinibni o'z ichiga olgan mahsulotlarni ishlab chiqish va tijoratlashtirish uchun Turning Point Therapeutics, Inc.; Durlobaktamni Sulbaktam bilan ishlab chiqish va tijoratlashtirish uchun Entasis Therapeutics Holdings Inc.; va Xanomelin va trospium xloridini ishlab chiqish va tijoratlashtirish uchun Karuna Therapeutics, Inc., shuningdek, Tisotumab Vedotin uchun Pfizer Inc. bilan strategik hamkorlikni amalga oshiradi. Kompaniya 2013-yilda tashkil etilgan va Xitoyning Pudong shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of R&D |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Joshua L. Smiley | President & COO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-11-06 | 10-Q | zlab-20250930.htm |
| 2025-10-16 | 8-K | zlab-20251013.htm |
| 2025-08-07 | 8-K | zlab-20250807.htm |
| 2025-06-18 | 8-K | zlab-20250618.htm |
| 2025-05-08 | 8-K | zlab-20250508.htm |
| 2025-04-29 | DEFA14A | a2025defa14a.htm |
| 2025-04-18 | PRE 14A | zlab-20250418.htm |
| 2025-02-27 | 8-K | zlab-20250227.htm |
| 2025-01-03 | 8-K | zlab-20250102.htm |
| 2024-11-15 | 8-K | d781798d8k.htm |
| Mr. Tong Zhu |
| Chief Commercial Officer of Greater China |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations |